文献速递角膜与眼表疾病眼底病与葡萄膜炎神经眼科

黏多糖贮积症眼部表型的变异性研究

Variability in the ocular phenotype in mucopolysaccharidosis.
PubMed 文献 · Br J Ophthalmol · 2018-08-17

该前瞻性观察队列研究纳入21例MPSI、4例MPSIV和3例MPSVI患者,进行详细眼科检查并收集基因型、生物标志物和治疗数据。结果显示角膜混浊评分MPSI高于MPSIV和MPSVI,视网膜病变仅见于MPSI;角膜混浊与生物标志物相关,但基因型或治疗类型与眼部表型无明确关联。

要点

  • 角膜混浊见于MPSI、MPSIV和MPSVI,MPSI评分更高。
  • 视网膜病变仅见于MPSI患者。
  • 角膜混浊与生物标志物相关,与基因型或治疗类型无明确关联。

核心结论

  • MPS眼部表型具有变异性,角膜混浊见于MPSI、MPSIV和MPSVI,视网膜病变仅见于MPSI。
  • 角膜混浊与反映系统性治疗疗效的生物标志物存在关联。

研究设计与样本

  • 前瞻性观察队列研究,纳入21例MPSI、4例MPSIV和3例MPSVI患者。
  • 患者接受详细眼科检查,包括视力、角膜混浊评估(Iris相机角膜混浊度量评分和Pentacam密度测定)以及视网膜和视神经成像(OCT和广角眼底成像)。
  • 收集基因型、生物标志物和已接受治疗(类型和治疗时长)数据。

主要发现

  • 角膜混浊评分MPSI高于MPSIV和MPSVI。
  • 视网膜病变仅见于MPSI患者。
  • MPSI、MPSIV和MPSVI中均观察到角膜混浊与生物标志物的关联。
  • 基因型或治疗类型与眼部表型之间未见明确关联。

临床怎么用

  • 对MPS患者应进行详细眼科检查,包括角膜混浊定量评估和视网膜、视神经成像。
  • MPSI患者需重点关注视网膜病变,MPSI、MPSIV和MPSVI患者均需评估角膜混浊。
  • 生物标志物可能有助于监测角膜混浊与系统性治疗疗效的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Mucopolysaccharidoses (MPSs) are a heterogeneous group of lysosomal storage disorders. Ocular complications (such as corneal clouding, retinopathy and optic neuropathy) are common. Notably, there is a paucity of data on the effect of genotype and systemic treatments (enzyme replacement therapy or haematopoietic stem cell transplantation) on the ocular phenotype in MPS. We prospectively studied the ocular features of patients with MPSI (Hurler/Hurler-Scheie/Scheie), MPSIV (Morquio) and MPSVI (Maroteaux-Lamy), to evaluate the effect of different therapeutic interventions and to correlate the findings with genetic and biomarker data. METHODS: Prospective observational cohort study. Study participants underwent detailed ocular examination including visual acuity; assessment of corneal clouding (Iris camera Corneal Opacification Measure score and Pentacam densitometry) and retinal and optic nerve imaging (optical coherence tomography and wide-field fundus imaging). Data on genotype, biomarkers and delivered therapies (type and length of treatment) were also collected for each patient where available. RESULTS: Overall, 21 patients with MPSI, 4 patients with MPSIV and 3 patients with MPSVI were recruited. Corneal clouding scores were higher in MPSI compared with MPSIV and MPSVI. Retinopathy was evident in patients with MPSI only. Association was observed between corneal clouding and biomarkers in MPSI, MPSIV and MPSVI. However, no clear association was seen between genotype or treatment type and ocular phenotype. CONCLUSIONS: The ocular phenotype in MPS is variable, with corneal clouding occurring in MPSI, MPSIV and MPSVI, and retinopathy in MPSI only. There was an association between corneal clouding and efficacy of systemic treatment as measured by biomarkers.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sornalingam K, Javed A, Aslam T, et al. Variability in the ocular phenotype in mucopolysaccharidosis. Br J Ophthalmol. 2018. PMID: 30120129. doi:10.1136/bjophthalmol-2017-311749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。